Lisdexamfetamine Dimesylate Capsule
Product Images NDC 72162-2454

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 72162-2454). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622454)

Label for Lisdexamfetamine Dimesylate Capsules 30 mg by Bryant Ranch Prepack. The label indicates 100 capsules, Rx only, and includes storage instructions. It shows NDC 72162-2454-1, manufacturer Purdue Pharma L.P., and has QR codes for package insert and dosage information.*

FDA Label Image

Chemical Structure (Lisdexcaps 01)

Chemical structure of lisdexamfetamine dimesylate, depicting the molecular arrangement with an amino acid linked to a phenyl ring and associated with two mesylate groups.*

FDA Label Image

Figure 1 (Lisdexcaps 02)

A chart depicting pharmacokinetic fold change and 90% confidence intervals for lisdexamfetamine dimesylate across special populations including gender, age groups 65-74 years and ≥75 years, renal impairment (mild, moderate, severe), and end stage renal disease. The graph shows changes in Cmax and AUC relative to a reference on a horizontal axis ranging from 0.0 to 2.5 fold change.*

FDA Label Image

Figure 2 (Lisdexcaps 03)

A forest plot chart showing the fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC for Guanfacine, Venlafaxine, and Omeprazole. The x-axis represents change relative to reference, ranging from 0.0 to 2.0. Data points indicate how these drugs' pharmacokinetics vary under unspecified conditions.*

FDA Label Image

Figure 3 (Lisdexcaps 04)

A scatter plot showing fold change and 90% confidence intervals in pharmacokinetic parameters (Cmax and AUC) for various interacting drugs relative to a reference. Interacting drugs listed include Guanfacine, Venlafaxine, caffeine (CYP1A2 substrate), dextromethorphan (CYP2D6 substrate), omeprazole (CYP2C19 substrate), and midazolam (CYP3A substrate). The x-axis represents change relative to the reference from 0.0 to 2.0 fold.*

FDA Label Image

Figure 4 (Lisdexcaps 05)

A line graph comparing LS Mean SKAMP Deportment Scores over time post-dose (hours) between Lisdexamfetamine and placebo. The x-axis indicates time from -0.5 to 13 hours post-dose, and the y-axis shows mean scores ranging from 0.1 to 1.9 with error bars. The graph shows placebo scores increasing, while Lisdexamfetamine scores decrease initially then rise slowly toward the end.*

FDA Label Image

Figure 5 (Lisdexcaps 06)

A Kaplan-Meier curve showing the proportion of subjects with relapse or treatment failure over time (days after randomization). Two lines compare lisdexamfetamine treatment, which shows a lower proportion of relapse, versus placebo, which shows a higher and increasing relapse proportion over the 50-day period.*

FDA Label Image

Figure 6 (Lisdexcaps 07)

Line graph showing LS Mean (SE) PERMP Total Scores over time post-dose (hours) comparing Lisdexamfetamine and Placebo. The x-axis represents time post-dose from -0.5 to 14 hours, and the y-axis shows score values ranging approximately from 250 to 330. Lisdexamfetamine shows higher scores than placebo throughout the observation period, with error bars indicating variability.*

FDA Label Image

Figure 7 (Lisdexcaps 08)

A line graph showing the proportion of subjects with relapse or treatment failure (%) over time (days after randomization) comparing placebo versus lisdexamfetamine. The placebo group shows a steadily increasing relapse rate up to about 75%, while the lisdexamfetamine group remains low at around 10% through approximately 30 days.*

FDA Label Image

Figure 8 (Lisdexcaps 09)

A Kaplan-Meier survival curve chart plotting the proportion of subjects with relapse (%) over time in days after randomization. Two groups are compared: Lisdexamfetamine (solid line) and placebo (dashed line). The chart includes numbers of subjects at risk for each group at multiple time points along the x-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.